SCHEMBL29573969

SCHEMBL29573969

CCNc1nc(Cl)nc2c1ncn2[C@H]1[C@@H]2OC(C)(C)O[C@@H]2[C@]2(C(F)F)C[C@H]12

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HRH2 P25021 1/20 0.54
▸ HTR5A P47898 1/20 0.54
▸ ADORA3 P0DMS8 14/20 0.50
▸ ADORA1 P30542 11/20 0.50
▸ HTR2B P41595 12/20 0.43
▸ HTR2C P28335 8/20 0.43
▸ ADORA2A P29274 6/20 0.43
▸ TMIGD3 P0DMS9 3/20 0.43
▸ SLC6A3 Q01959 1/20 0.41
▸ HTR1D P28221 3/20 0.41
▸ ADRA2B P18089 1/20 0.41
▸ ADRA2C P18825 2/20 0.41
▸ ADRB3 P13945 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ HTR2A P28223 1/20 0.40
▸ OPRM1 P35372 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29573820 0.86 HRH2 (0.44) HRH2HTR5AADORA3ADORA1HTR2B
SCHEMBL29574031 0.83 HRH2 (0.40) HRH2HTR5AADORA3ADORA1HTR2B
SCHEMBL29573470 0.83 ADORA3 (0.62) ADORA3ADORA1HTR2BHTR2CADORA2A
SCHEMBL29573875 0.82 HRH2 (0.53) HRH2HTR5AADORA3ADORA1HTR2B
SCHEMBL29574073 0.79 HTR2B (0.51) HRH2HTR5AADORA3ADORA1HTR2B
SCHEMBL29573609 0.78 ADORA3 (0.41) HRH2HTR5AADORA3ADORA1HTR2B
SCHEMBL31350105 0.74 HTR2B (0.71) HRH2HTR5AADORA3ADORA1HTR2B
SCHEMBL31350147 0.73 HTR2B (0.70) HRH2HTR5AADORA3ADORA1HTR2B
SCHEMBL29574455 0.73 ADORA3 (0.55) ADORA3ADORA1HTR2BHTR2CADORA2A
SCHEMBL31350257 0.73 HTR2B (0.71) HRH2HTR5AADORA3ADORA1HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4196219-A1 A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE Biointervene, Inc. (US) 2023-06-21 — — EP disclosed
WO-2022040241-A1 A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE BIOINTERVENE, INC. (US) 2022-02-24 — — WO disclosed
Send feedback